The talk will cover both innate and adaptive immune aspects potentially driving pathology following SARS-CoV-2 infection. Applying their immune monitoring experience to large patient cohorts hospitalized at Mount Sinai in New York during the COVID-19 epidemic, Sacha Gnjatic and his team investigated cytokine and antibody profiles. They found that levels of IL-6, TNF-alpha, and antiviral immunoglobulins are helpful in predicting severity and survival outcome, and may be useful to stratify patients and guide tailored therapies.
Sacha Gnjatic is an associate professor and the co-director of the Human Immune Monitoring Center at Mount Sinai. After obtaining his PhD evaluating p53 as a tumor antigen in Paris, he trained with Dr. Lloyd Old at the Ludwig Institute in New York where he studied T cell and antibody responses specific to NY-ESO-1, in particular for antigen presentation and tolerance mechanisms. As a tumor immunologist, he specializes in studying immune correlates, both circulating and tissue-based, to define biomarkers of immunotherapies from human clinical trials.
Miriam Merad, M.D.; Ph.D. is the Mount Sinai Chair professor in Cancer Immunology and the Director of the Precision Immunology Institute at Mount Sinai School of Medicine in New York. Dr. Merad also co-Directs, the Cancer Immunology program at The Mount Sinai Tisch Cancer Institute and is the Director of the Mount Sinai Human Immune Monitoring Center (HIMC).
Miriam Merad is the Vice-President of IUIS.